Beam Therapeutics develops precision genetic medicines for serious diseases. Products include BEAM-101 for sickle cell/beta-thalassemia, BEAM-302 for alpha-1 antitrypsin deficiency, and BEAM-201/BEAM-301 for T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma and glycogen storage disease 1a. The company has research collaborations with Pfizer, Apellis Pharmaceuticals, Verve Therapeutics, Sana Biotechnology, and Orbital Therapeutics. These partnerships focus on rare genetic diseases of the liver, muscle, central nervous system, cardiovascular disease, complement system, and cell therapy programs. Beam Therapeutics was incorporated in 2017 and is based in Cambridge, Massachusetts.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.3 |